Complete resolution of chronic cutaneous leishmaniasis by combination therapy with systemic Glucantime, oral fluconazole and 50% trichloroacetic acid solution: report of one case

Authors

  • Haftbaradaran Elaheh
  • Nilforoushzadeh Mohammad Ali
  • Siadat Amir Hossein
Abstract:

Cutaneous leishmaniasis is an endemic disease in Iran and there is no curative treatment. The disfiguring scar that remains after it subsides is a major psychologic and emotional problem in these patients. Chronic leishmaniasis is a rare form of this malady which is seen in 5-7 percent of cases. In this article we report a 46-year-old man who was refered to us for a large leishmaniasis lesion consisting of a scaling erythematous plaque with several papules on the right side of face and nose. This patient was treated by a combination of systemic Glucantime, 50% trichlroacetic acid and oral fluconazole. Complete resolution was achieved after 4 months.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Comparison of efficacy of oral Fluconazole with intramuscular Glucantime in patients with acute cutaneous Leishmaniasis

Background: Cutaneous leishmaniasis is an important skin parasitic disease. Ideal treatment is not found yet and seeking for proper drugs continues. Objective: Comparison of the efficacy of fluconazole with systemic glucantime in patients with acute cutaneous leishmaniasis in Ghaem hospital in Mashhad in 2002. Patients and Methods: During one year of study, all patients with cutaneous leishmani...

full text

Treatment of GlucantimTM - Resistant Cutaneous Leishmaniasis Using Combination Therapy of Allopurinol and Trichloroacetic Acid (TCA) 50%; Report of Three Cases

Background: There are 3 main forms of leishmaniasis-visceral, cutaneous, and mucocutaneous. Leishmania parasites are transmitted by the bite of infected female phlebotomine sand flies. Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and causes skin lesions, leaving life-long scars and serious disability. About 95% of CL cases occur in the Americas, the Mediterranean basin,...

full text

Comparison of 50% trichloroacetic acid and CO2 laser in the treatment of cutaneous leishmaniasis scar

Background and aim: The scars of the cutaneous leishmaniasis and psychologic problems of this disease needs different intervention for its correction. Our objective in this study was to compare the efficacy of trichloroacetic acid (TCA) 50 percent solution and CO2 laser for treatment of the atrophic scars due to leishmaniasis. Materials and methods: This was a randomized clinical trial perfomed...

full text

omparative study of oral azithromycin and systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis

Background and aim: Complications and resistance to pentavalent antimonial agents in cutaneous leishmaniasis, exhibit the need for effective alternative drugs. The aim of this study was to compare the efficacy of oral azithromycin with systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Materials and Methods: Forty-seven patients with cutaneous leishmaniasis...

full text

A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions.

Background. Cutaneous leishmaniasis is an endemic disease in Iran. Pentavalent antimonial drugs have been the first line of therapy in cutaneous leishmaniasis for many years. However, the cure rate of these agents is still not favorable. This study was carried out to compare the efficacies of intralesional glucantime with topical trichloroacetic acid 50% (TCA 50%) + glucantime and fractional ca...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 10  issue 3

pages  240- 244

publication date 2007-10-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023